Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Oncology
|
| gptkbp:associated_with |
gptkb:neurofibromatosis_type_1
gptkb:hereditary_nonpolyposis_colorectal_cancer gptkb:Li-Fraumeni_syndrome gptkb:Turcot_syndrome genetic mutations |
| gptkbp:characterized_by |
rapid growth
necrosis infiltrative nature |
| gptkbp:clinical_trial |
ongoing
heterogeneous appearance may have midline shift may present with edema often multifocal |
| gptkbp:death |
less than 5% at 5 years
|
| gptkbp:diagnosis |
gptkb:MRI
CT scan poor |
| gptkbp:epidemiology |
higher incidence in Caucasians
increased incidence in women often arises from low-grade gliomas |
| gptkbp:genetic_alterations |
gptkb:TP53_mutation
ATRX loss EGFR amplification PTEN loss IDH1 mutation |
| https://www.w3.org/2000/01/rdf-schema#label |
secondary glioblastoma
|
| gptkbp:is_common_in |
adults
|
| gptkbp:occurs_in |
1-2 per 100,000 people
|
| gptkbp:originated_in |
previous cancer
|
| gptkbp:research_focus |
gptkb:immunotherapy
biomarkers targeted therapy |
| gptkbp:risk_factor |
age
radiation exposure previous cancer history |
| gptkbp:symptoms |
cognitive decline
headache nausea vomiting seizures vision problems weakness personality changes |
| gptkbp:treatment |
gptkb:surgery
palliative care variable clinical trials side effects supportive care radiation therapy chemotherapy recurrence resistance to therapy |
| gptkbp:type |
gptkb:Oncology
|
| gptkbp:bfsParent |
gptkb:Oncology
|
| gptkbp:bfsLayer |
4
|